Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
JAMA
    October 2026
  1. FAN Y, Liu Y, Wang Y, Ouyang Q, et al
    Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial.
    JAMA. 2026 Oct 23:e2621372. doi: 10.1001/jama.2026.21372.
    >> Share


  2. Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: Research Summary.
    JAMA. 2026 Oct 23:e2621700. doi: 10.1001/jama.2026.21700.
    >> Share

  3. MOSELE MF, Andre F
    Trastuzumab Rezetecan in EBBR2-Low Metastatic Breast Cancer: One More ADC or a New Opportunity?
    JAMA. 2026 Oct 23. doi: 10.1001/jama.2026.22295.
    >> Share

  4. ANGUS DC, O'Connor MB, Young LJ
    Breast Cancer's Transformation From Terminal to Manageable: A Healthy Dialogue With Nancy E. Davidson.
    JAMA. 2026 Oct 22:e2621078. doi: 10.1001/jama.2026.21078.
    >> Share

    July 2026
  5. RUBIN R
    Breast Cancer Recommendations Fuel Debate Over Who Should Write Screening Guidelines.
    JAMA. 2026 Jul 17. doi: 10.1001/jama.2026.7095.
    >> Share

    April 2026
  6. ESSERMAN LJ, Olopade OI, Eklund M
    Screening for Breast Cancer-Reply.
    JAMA. 2026 Apr 6. doi: 10.1001/jama.2026.1269.
    >> Share

  7. PESAPANE F, Cassano E
    Screening for Breast Cancer.
    JAMA. 2026 Apr 6. doi: 10.1001/jama.2026.1263.
    >> Share

  8. SMIT F, Kaufman JS, Chiolero A
    Screening for Breast Cancer.
    JAMA. 2026 Apr 6. doi: 10.1001/jama.2026.1266.
    >> Share

    February 2026
  9. PLEASANT V, Ring K
    What Systemic Hormone Therapy Black Box Removal Means for Breast Cancer Survivors.
    JAMA. 2026 Feb 5. doi: 10.1001/jama.2026.0025.
    >> Share

    December 2025

  10. Risk-Based vs Annual Breast Cancer Screening: Research Summary.
    JAMA. 2025 Dec 12:e2524865. doi: 10.1001/jama.2025.24865.
    >> Share

  11. ESSERMAN LJ, Fiscalini AS, Naeim A, Van't Veer LJ, et al
    Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.
    JAMA. 2025 Dec 12:e2524784. doi: 10.1001/jama.2025.24784.
    >> Share

  12. BAXTER NN, Phillips KA
    Unlocking the Potential of Risk-Based Screening for Breast Cancer: From Detection to Prevention.
    JAMA. 2025 Dec 12. doi: 10.1001/jama.2025.24817.
    >> Share

    October 2025
  13. PANT S
    Lesser-Known Lobular Breast Cancer on the Rise.
    JAMA. 2025 Oct 24. doi: 10.1001/jama.2025.17524.
    >> Share

    April 2025
  14. FAN L, Shao ZM
    Camrelizumab vs Placebo in Patients With Triple-Negative Breast Cancer.
    JAMA. 2025 Apr 23. doi: 10.1001/jama.2025.1294.
    >> Share

  15. PEI YY
    Camrelizumab vs Placebo in Patients With Triple-Negative Breast Cancer.
    JAMA. 2025 Apr 23. doi: 10.1001/jama.2025.1291.
    >> Share

    March 2025
  16. HWANG ES, Hyslop T, Lynch T, Ryser MD, et al
    Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial.
    JAMA. 2025;333:972-980.
    >> Share

  17. ANDERER S
    Trial: Less Frequent Mammograms Pose No Greater Risk After Breast Cancer.
    JAMA. 2025 Mar 7. doi: 10.1001/jama.2025.1346.
    >> Share

  18. LIM WH
    Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
    JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27807.
    >> Share

  19. WESTHOFF CL, Pike MC, Pearce CL
    Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
    JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27795.
    >> Share

  20. LUO P, Lin A, Miao K
    Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
    JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27804.
    >> Share

  21. SLOTH MMB, Jorgensen TSH, Nybo Andersen AM
    Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
    JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27798.
    >> Share

  22. LIBERTY AL, Rodriguez MI, Edelman A
    Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
    JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27810.
    >> Share

  23. MORCH LS, Meaidi A, Corn G
    Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems-Reply.
    JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27801.
    >> Share

    January 2025
  24. HUNTER N, Hurvitz S
    Where Did the Passion Go?-Rethinking Adjuvant Immune Therapy for Triple-Negative Breast Cancer.
    JAMA. 2025 Jan 30. doi: 10.1001/jama.2024.26811.
    >> Share

  25. IGNATIADIS M, Bailey A, McArthur H, El-Abed S, et al
    Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial.
    JAMA. 2025 Jan 30. doi: 10.1001/jama.2024.26886.
    >> Share

    December 2024
  26. JOENSUU H
    Neoadjuvant Camrelizumab for Triple-Negative Breast Cancer.
    JAMA. 2024 Dec 13. doi: 10.1001/jama.2024.25927.
    >> Share

  27. CHEN L, Li H, Zhang H, Yang H, et al
    Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.
    JAMA. 2024 Dec 13. doi: 10.1001/jama.2024.23560.
    >> Share

    November 2024
  28. ANDERER S
    ACOG Now Recommends Breast Cancer Screenings Start at Age 40.
    JAMA. 2024 Nov 15. doi: 10.1001/jama.2024.23048.
    >> Share

  29. ANDERER S
    Study: BMI May Underestimate Obesity-Linked Breast Cancer Risk.
    JAMA. 2024 Nov 15. doi: 10.1001/jama.2024.23049.
    >> Share

  30. ORRALL A
    Breast Cancer Incidence Still Rising Despite Decline in Death Rates.
    JAMA. 2024 Nov 1. doi: 10.1001/jama.2024.22056.
    >> Share

    October 2024
  31. MORCH LS, Meaidi A, Corn G, Hargreave M, et al
    Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems.
    JAMA. 2024 Oct 16. doi: 10.1001/jama.2024.18575.
    >> Share

    September 2024
  32. THORAT MA, Cuzick J, Chan AT
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15497.
    >> Share

  33. PETRELLI F, Ghidini A
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15491.
    >> Share

  34. LI C, He J, Liang W
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15488.
    >> Share

  35. SUN R, Wei LJ
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15494.
    >> Share

  36. CHEN WY, Ballman KV, Holmes MD
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer-Reply.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15500.
    >> Share

  37. RYAN CE, Fasaye GA, Gallanis AF, Gamble LA, et al
    Germline CDH1 Variants and Lifetime Cancer Risk.
    JAMA. 2024;332:722-729.
    >> Share

    August 2024
  38. HARRIS E
    More Data About Risks, Benefits Might Change Breast Cancer Screening Choice.
    JAMA. 2024 Aug 2. doi: 10.1001/jama.2024.13777.
    >> Share

    July 2024
  39. LEON-FERRE RA, Salgado R, Jonas SF
    Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Triple-Negative Breast Cancer-Reply.
    JAMA. 2024 Jul 3. doi: 10.1001/jama.2024.10483.
    >> Share

  40. TU H, Zhang Y, You Z
    Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Triple-Negative Breast Cancer.
    JAMA. 2024 Jul 3. doi: 10.1001/jama.2024.10480.
    >> Share

    June 2024
  41. RUBIN R
    Despite New Recommendations, the Debate Over Mammography Guidelines Continues.
    JAMA. 2024;331:1877-1879.
    >> Share

    May 2024
  42. MANSON JE, Crandall CJ, Rossouw JE, Chlebowski RT, et al
    The Women's Health Initiative Randomized Trials and Clinical Practice: A Review.
    JAMA. 2024;331:1748-1760.
    >> Share

  43. MANDELBLATT JS, Mainor C, Hudson BI
    The Aspirin Conundrum-Navigating Negative Results, Age, Aging Dynamics, and Equity.
    JAMA. 2024;331:1709-1711.
    >> Share

  44. HARRIS E
    Young Patients Without Genetic Risk Have Low Chance of Second Breast Cancer.
    JAMA. 2024 May 3. doi: 10.1001/jama.2024.6734.
    >> Share

    April 2024
  45. TRENTHAM-DIETZ A, Chapman CH, Jayasekera J, Lowry KP, et al
    Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A Decision Analysis for the US Preventive Services Task Force.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2023.24766.
    >> Share

  46. NICHOLSON WK, Silverstein M, Wong JB, Barry MJ, et al
    Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2024.5534.
    >> Share

  47. HENDERSON JT, Webber EM, Weyrich MS, Miller M, et al
    Screening for Breast Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2023.25844.
    >> Share


  48. Screening for Breast Cancer.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2024.5535.
    >> Share

  49. ELMORE JG, Lee CI
    Toward More Equitable Breast Cancer Outcomes.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2024.6052.
    >> Share

  50. CHEN WY, Ballman KV, Partridge AH, Hahn OM, et al
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial.
    JAMA. 2024 Apr 29:e244840. doi: 10.1001/jama.2024.4840.
    >> Share

  51. CASWELL-JIN JL, Kurian AW, Plevritis SK
    US Breast Cancer Mortality-Reply.
    JAMA. 2024 Apr 25. doi: 10.1001/jama.2024.5482.
    >> Share

  52. JATOI I
    US Breast Cancer Mortality.
    JAMA. 2024 Apr 25. doi: 10.1001/jama.2024.5479.
    >> Share

  53. NAROD SA
    Breast Cancer and Pregnancy in Young BRCA Carriers.
    JAMA. 2024;331:1233-1234.
    >> Share

  54. BLONDEAUX E, Partridge AH, Lambertini M
    Breast Cancer and Pregnancy in Young BRCA Carriers-Reply.
    JAMA. 2024;331:1234.
    >> Share

  55. LEON-FERRE RA, Jonas SF, Salgado R, Loi S, et al
    Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
    JAMA. 2024;331:1135-1144.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016